MOSAIC Safety Update Supports FOLFOX4 Use in Colon Cancer

Allison Gandey

July 27, 2007

July 27, 2007 (Chicago) — New 5-year data confirm earlier 3-year results that FOLFOX4 improves disease-free survival in colon cancer. The safety update was presented at the recent American Society of Clinical Oncology 43rd Annual Meeting. Investigators from the Multicenter International Study of Oxaliplatin, 5-Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) study showed that patients followed beyond the 3-year cutoff for the trial experienced a significant benefit from therapy.

"In addition," lead author and presenter Aimery de Gramont, MD, from the Hôpital Saint Antoine, in Paris, France, said, "at a median follow-up of 6 years, the study demonstrates a significant benefit in overall survival for stage 3 patients."

The MOSAIC trial looked at more than 2200 patients who had undergone resection for stage 2 or 3 colon cancer. Participants were randomly assigned to receive 5-fluorouracil and leucovorin (LV5FU2) alone or with oxaliplatin (FOLFOX4) every 2 weeksfor 12 cycles.

MOSAIC showed that for the overall population, treatment with FOLFOX4 resulted in a significant benefit in disease-free survival — 78.2% vs 72.9% (hazard ratio, 0.77; P = .002). In this latest analysis, patients were followed for longer. "Final disease-free survival at 5-year follow-up is consistent with earlier results — hazard ratio 0.80, P = .003," Dr. de Gramont said.

Probability of Surviving at 6 Years
LV5FU2 (%)
Hazard Ratio (95% CI)
Overall population
0.85 (0.71 – 1.01)
Stage 2
1.00 (0.70 – 1.43)
Stage 3
0.80 (0.66 – 0.98)
Presenting at a second conference in June — the 9th World Congress on Gastrointestinal Cancer in Barcelona, Spain — Dr. de Gramont showed that at a median of 6 years of follow-up, no survival benefit was seen for stage 2 patients. For stage 3 cases, they observed a 4.6% absolute difference in the probability of surviving at 6 years. "It translated in a significant survival advantage," the investigators noted in their abstract, "with a reduction in the risk of death of 20%."

"Longer follow-up confirms the benefit of FOLFOX4, showing that the benefit of prevention of relapse already seen now actually translates into a survival advantage for patients with stage 3 colon cancer," the team reported. Dr. de Gramont pointed out that long-term data show no increase in the rate of secondary cancer (5.0% in both treatment groups). The group concludes, "These results confirm the benefit of the FOLFOX4 regimen in adjuvant colon cancerpatients."

American Society of Clinical Oncology 43rd Annual Meeting: Abstract 4007. Presented June 3, 2007.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.